Cytavis Biopharma GmbH Report issue

For profit Phase 2
Founded: Hamburg Germany (2005)
Status: Defunct (2013)

Organization Overview

First Clinical Trial
2008
NCT00658437
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

Aviscumine (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Melanoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1